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Establishing the in vivo activation status of G protein-coupled
receptors would not only indicate physiological roles of G pro-
tein-coupled receptors but would also aid drug discovery by
establishing drug/receptor engagement. Here, we develop a
phospho-specific antibody-based biosensor to detect activation
of the M1 muscarinic acetylcholine receptor (M1 mAChR) in
vitro and in vivo. Mass spectrometry phosphoproteomics iden-
tified 14 sites of phosphorylation on the M1 mAChR. Phospho-
specific antibodies to four of these sites established that serine at
position 228 (Ser228) on the M1 mAChR showed extremely low
levels of basal phosphorylation that were significantly up-regu-
lated by orthosteric agonist stimulation. In addition, the M1
mAChR-positive allosteric modulator, 1-(4-methoxybenzyl)-4-
oxo-1,4-dihydroquinoline-3-carboxylic acid, enhanced acetyl-
choline-mediated phosphorylation at Ser228. These data sup-
ported the hypothesis that phosphorylation at Ser228 was an
indicator of M1 mAChR activation. This was further supported
in vivo by the identification of phosphorylated Ser228 on the M1
mAChR in thehippocampusofmice following administrationof
themuscarinic ligands xanomeline and 1-(4-methoxybenzyl)-4-
oxo-1,4-dihydroquinoline-3-carboxylic acid. Finally, Ser228
phosphorylation was seen to increase in the CA1 region of the
hippocampus following memory acquisition, a response that
correlated closely with up-regulation of CA1 neuronal activity.
Thus, determining the phosphorylation status of the M1
mAChR at Ser228 not only provides a means of establishing
receptor activation followingdrug treatment both in vitro and in
vivo but also allows for the mapping of the activation status of
the M1 mAChR in the hippocampus following memory acquisi-
tion thereby establishing a link between M1 mAChR activation
and hippocampus-based memory and learning.
G protein-coupled receptors (GPCRs)3 respond to the bind-
ing of their cognate ligands by transitioning from an inactive to
an active conformation capable of engaging with intracellular
signaling cascades (1–3). Whereas this process has been
described in exquisite pharmacological detail (4, 5), and bio-
physically in recent crystal structures (2, 6), correlating the acti-
vation state of a GPCR subtype in vivo to a physiological
response or drug treatment is extremely challenging and pres-
ents a considerable barrier to establishing the physiological role
of GPCRs and the on-target action of GPCR ligands.
Progress in this area has been made in transfected systems
where it has been possible to monitor receptor conformational
changes in response to ligand occupation using fluorescent res-
onance energy transfer (FRET). In these studies, changes in the
energy transfer between FRET-acceptor and FRET-donormoi-
eties, engineered within the receptor sequence, provide a read-
out of changes in receptor conformation on agonist binding
(7–10). Alternatively, a green fluorescent protein (GFP) biosen-
sor based on a conformation-sensitive antibody (nanobody-80,
Nb80) that preferentially recognizes the active state of the
2-adrenoreceptor has recently been employed to determine
the active conformation of the2-adrenoreceptor at the plasma
membrane and within intracellular compartments (11). These
approaches, however, require transfection of either mutated
receptors (7–10) or a GFP biosensor (11), and therefore,
although able to monitor receptor conformational changes
quantitatively in living cells in real time, are restricted to heter-
ologous systems.
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An alternative approach considered here is to monitor the
phosphorylation status of GPCRs as a read-out of receptor acti-
vation. This is based on the “classical” principle that the con-
formation adopted by a receptor upon agonist occupation
reveals phosphorylation sites, often within the third intracellu-
lar loop and C-terminal tail, that otherwise are not accessible in
the inactive receptor conformation (12). In this scenario, the
phosphorylation status of a particular GPCR may serve as a
read-out of the proportion of receptors that have adopted an
active conformation. Therefore, phospho-specific antibodies to
agonist-dependent receptor phosphorylation events could
potentially be used as a probe for the activated receptor in not
only recombinant systems, but also in physiologically relevant
tissues. If this were the case, then it might be possible to corre-
late the activation status ofGPCRswith physiological responses
and, importantly for drug discovery, could be used to assess
receptor engagement with synthetic ligands.
We test this notion here by focusing on the M1-muscarinic
acetylcholine receptor (M1 mAChR), which is one of five mus-
carinic receptor subtypes (M1–M5) that respond to the natural
ligand acetylcholine and is a subtype that has been implicated in
a number of neurological processes (13, 14)most notably learn-
ing and memory (15–17). We have shown previously that this
receptor subtype is rapidly phosphorylated by agonist addition
likely via members of the G protein-coupled receptor kinase
family (18), although the involvement of other receptor kinases
has not been ruled out. Here, we usedmass spectrometry-based
phosphoproteomics to determine the sites of receptor phos-
phorylation from which we developed a series of phospho-spe-
cific antibodies. This included an antibody to phosphoserine
228 (Ser(P)228) in the third intracellular loop, which we show is
a phosphorylation event highly sensitive to agonist stimulation.
This antibody was used here to probe the phosphorylation sta-
tus of the M1 mAChR following engagement with orthosteric
and allosteric muscarinic ligands, both in vitro and in vivo. Fur-
thermore, this antibody was used to determine that the M1
mAChR was activated in specific regions of the hippocampus
following fear conditioning in a manner that maps to the
regions of the hippocampus showing increased synaptic activity
during memory acquisition. In this way we not only link the
activation status of the M1 mAChR to memory acquisition but
also establish the principle that phosphorylation sites can be
used to probe the activation status of GPCRs during physiolog-
ical responses and on drug treatment.
Experimental Procedures
Materials—Unless otherwise stated, all chemicals were pur-
chased from Sigma. Xanomeline was obtained from Lilly (Erl
Wood Manor, Windlesham, Surrey, UK).
Generation of Cell Lines—Chinese hamster ovary (CHO)
cells that stably and constitutively expressed theC-terminalHA
epitope-tagged mouse M1 mAChR (CHO-M1 cells) were gen-
erated using the Flp-InTM system. CHO Flp-In cells were co-
transfected with pcDNA5FRT containing M1 mAChR and
pOG44, and transfected cells were selected with hygromycin B,
and expression of M1 mAChR was confirmed by immunoblot-
tingwith anti-HA antibodies and byN-[3H]methylscopolamine
(NMS) radioligand binding.
[32P]Orthophosphate Labeling and Immunoprecipitation—
Cells were plated in 6-well plates at 200,000 cells/well 24 h
before experimentation. For phosphorylation experiments,
cells were washed three times with Krebs/HEPES buffer with-
out phosphate (118 mM NaCl, 1.3 mM CaCl2, 4.3 mM KCl,1.17
MgSO4, 4.17 mM NaHCO3, 11.7 mM glucose, 10 mM HEPES
(pH 7.4)) and incubated in this buffer containing 100 Ci/ml
[32P]orthophosphate for 1 h at 37 °C. Cells were stimulated for
5 min with test compounds and immediately lysed by addition
of buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, 3 mM
EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate. The M1
mAChR was immunoprecipitated from the cleared lysates
using anti-HA affinity matrix (Roche Applied Science). The
washed immunoprecipitates were separated by SDS-PAGE on
8% gels that were then dried, and radioactive bands were
revealed using autoradiography film. The films were scanned
and bands were quantified using AlphaImager software (Alpha
Innotech, San Leandro, CA).
M1 mAChR Purification and Mass Spectrometry—Stably
transfected CHO-M1 cells expressing mouse HA-tagged M1
mAChRwere grownuntil confluent in expanded surface rolling
bottles at 0.25 rpm in a humidified CO2 incubator. For receptor
purification, cells from four rolling bottles were harvested,
resuspended in 40 ml of Krebs/HEPES buffer, and stimulated
with 100 M acetylcholine for 5 min. Membranes were then
prepared and solubilized by addition of 5 ml of PBS containing
1% Nonidet P-40 plus a mixture of protease and phosphatase
inhibitors (Complete, Roche Applied Science). After centrifu-
gation at 20,000  g, the resulting supernatant was diluted 1:1
with PBS, and the receptor was then purified on anti-HA affin-
ity matrix. After extensive washing with solubilization buffer
containing 0.5%Nonidet P-40, the resinwas resuspended in 2
SDS-PAGE sample buffer. The sample was resolved by SDS-
PAGE on 10% gels and stained with colloidal Coomassie Blue.
The band associatedwith theM1mAChRswas excised from the
polyacrylamide andwashed three times for 15minwith 100mM
triethylammonium bicarbonate (TEAB). Reduction and alkyla-
tion of cysteines were performed by addition of 10 mM dithio-
threitol in 50mMTEABat 60 °C for 30min followed by addition
of 100 mM iodoacetamide in 50 mM TEAB for 30 min in the
dark. Gel slices were washed three times for 5 min with 50 mM
TEAB containing 50% acetonitrile, finally resuspended in
TEAB containing 10% acetonitrile, and incubated overnight at
37 °C with 1 g of sequencing grade trypsin (Promega, South-
ampton, UK). The resulting tryptic peptides were dried and
resuspended in 1 ml of buffer containing 250 mM acetic acid
and 30% acetonitrile, and phosphorylated peptides were
enriched by addition of 20 l of PHOS-SelectTM iron affinity
resin and incubation at room temperature for 2 h with mixing.
After washing the resin twice with loading buffer and once with
water, tryptic phosphopeptides were eluted by addition of 200
l of buffer containing 400mM ammonium hydroxide and 30%
acetonitrile. LC-MS/MS was carried out on each sample using
an LTQOrbitrapmass spectrometer (ThermoFisher Scientific,
Rockford, IL). Peptides resulting from in-gel digestion were
loaded at a high flow rate onto a reverse-phase trapping column
(0.3-mm inner diameter  1 mm containing 5 m C18 300-Å
Acclaim PepMap medium (Dionex, UK) and eluted through a
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reverse phase capillary column (75-m inner diameter  150
mm) containing Symmetry C18 100-Å medium (Waters, Else-
tree, UK) that was self-packed using a high pressure packing
device (Proxeon Biosystems, Odense, Denmark). The resulting
spectra were searched against the UniProtKB/Swiss-Prot data-
base using Mascot (Matrix Science Ltd.) software with peptide
tolerance set to 5 ppm and the MS/MS tolerance set to 0.6 Da.
Fixed modifications were set as carbamidomethylcysteine with
variable modifications of phosphoserine, phosphothreonine,
phosphotyrosine, and oxidized methionine. The enzyme was
set to trypsin/Pro, and up to twomissed cleavageswere allowed.
Peptides with aMascot score greater than 20 and for which the
probability (p) that the observedmatchwas a randomeventwas
0.05 were included in the analysis. The spectra of peptides
reported as being phosphorylated were interrogated manually
to confirm the precise sites of phosphorylation.
Generation of M1 mAChR Antiserum and Phospho-specific
M1 mAChR Antiserum—Phosphorylation-specific antibodies,
anti-phosphoserine 228, 273, 322, and 451, were raised against
peptide sequences AALQGpSETPGKG, RLLQAYpSWKEEE,
KQPPKSpSPNTVK, and IPKRPGpSVHRTP corresponding to
amino acid residues 223–234, 267–278, 316–327, and 445–456
of themouseM1mAChR. The 87-day program,which included
four immunizations, was performed by Eurogentec. The result-
ing antisera were purified against the immunizing peptides. To
generate antibodies for immunoprecipitation and detection of
M1 AChR protein, rabbits and rats were immunized with the
peptide RDRGGKGQKPRGKEQ that corresponds to amino
acids 334–348 of the mouse M1 mAChR. The resulting antise-
rum was purified against the immunizing peptide.
Radioligand Binding Assays—CHO-M1 cell membranes (50
g/tube) were incubated in HEPES buffer (50 mM HEPES, 110
mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgSO4, 25 mM
glucose, 58mM sucrose (pH 7.4)) containing0.3 nM [3H]NMS
and increasing concentrations of acetylcholine in the presence
of various concentrations of BQCA. Incubations were contin-
ued for 1 h at 37 °C. Nonspecific binding and filtration were
carried out as above. Membrane-bound ligand was separated
from free ligand by rapid filtration onto GF/B glass microfiber
filters followed by three rapid washes with ice-cold 0.9% NaCl.
Membrane bound radioactivity was determined by liquid scin-
tillation (Ultima Gold, PerkinElmer Life Sciences) counting.
Nonspecific binding was determined by the inclusion of atro-
pine (1 M) during the incubation with [3H]NMS.
M1 mAChR Immunoprecipitation from Tissue Samples—To
establish the presence and phosphorylation status of M1
mAChRs in preparations from the hippocampus, tissues from
adult wild-type or adult M1 mAChR knock-out mice on a
C57Bl6/NTACbackgroundwere dissected into ice-coldHanks’
balanced salt solution buffer containing protease inhibitors and
phosphatase inhibitors (Complete, Roche Diagnostics). Mem-
branes were prepared and solubilized in buffer composed of 20
mM Tris (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 1% Nonidet
P-40. The receptor was immunoprecipitated with the anti M1
mAChR polyclonal antibody. Immune complexes were washed
three times in solubilization buffer and resuspended in 2
SDS-PAGE sample buffer. Receptors were separated by SDS-
PAGE on 8% gels, transferred PVDFmembranes, and immuno-
blotted with anti-phosphoserine 228 antibodies or antibodies
against the M1 mAChR protein.
Immunocytochemistry—CHO-M1 cells expressing mouse
HA-taggedM1AChRwere seeded onto 20-mm glass coverslips
for 24 h prior to experimentation. Cells were washed and incu-
bated for 1 h in Krebs/HEPES buffer prior to treatment. Cells
were fixed in PBS containing 4% paraformaldehyde and 0.1%
glutaraldehyde for 30 min at room temperature. Anti-HA anti-
body was used at 50 ng/ml followed by Alexa FluorTM 546 goat
anti rat secondary antibody at 1:1000. Anti-phospho-specific
serine 228 antibodies were used at 0.25 g/ml followed by goat
anti-rabbit Alexa FluorTM 488 secondary antibody at 1:1000.
Data were acquired using an Axiovert 200 M confocal laser
scanning microscope (Zeiss).
Total [3H]Inositol Phosphate Accumulation Assay—Cells
seeded at 100,000 cells/well in 24-well plates were labeled with
2.5 Ci/ml myo-[3H]inositol (PerkinElmer Life Sciences) for
24 h at 37 °C. Cells were washed twice in Krebs/HEPES buffer
(pH 7.4) and incubated with 10 mM LiCl for 20 min at 37 °C.
Appropriate concentrations of agonistwere added for 20min to
stimulate [3H]inositol phosphate production. Where the allos-
teric interactions were studied, cells were pre-incubated with
the allosteric modulator for 2 min prior to the addition of ago-
nist. Incubations were terminated by aspiration of buffer and
rapid addition of 500 l of ice-cold trichloroacetic acid (TCA)
(0.5 M). After extraction on ice for 20–30 min, samples were
transferred to tubes containing 100 l of EDTA (10 mM (pH
7.0)) and 500 l of a 1:1 mixture of tri-n-octylamine, and 1,1,2-
trichlorofluoroethane was added for 15 min at room tempera-
ture. After centrifugation at 20,000 g for 2 min, 400 l of the
upper aqueous phase was transferred to fresh tubes containing
60 mM NaHCO3. [3H]inositol mono-, bis-, and trisphosphate
([3H]InsPx) fractionwas recovered by anion-exchange chroma-
tography on Dowex AG1-X8 formate columns. Columns were
regenerated with 10 ml of ammonium formate (2 M)/formic
acid (0.1 M) and washed thoroughly with distilled water. Sam-
ples were applied to the columns and the columns washed with
10 ml of distilled water. Columns were then washed with
ammonium formate (60mM)/sodium tetraborate (10mM) solu-
tion. Total [3H]InsPx was eluted in 10 ml of ammonium for-
mate (0.75 M)/formic acid (0.1 M) and collected in large scintil-
lation vials. A 5-ml aliquot from the eluate was mixed with 10
ml of SafeFluor scintillation mixture, and radioactivity was
detected by liquid scintillation counting.
Fear Conditioning Training—Male C57Bl6/NTAC mice
(8–15 weeks old) were placed in the conditioning chamber
(Stoelting ANY-maze fear conditioning system), and after a
2-min adaptation period, the mice received three tone/foot
shock pairings, where a tone (conditioned stimulus, 2.8 kH, 85
db, 30 s) always co-terminated with the foot shock (uncondi-
tioned stimulus, 2 s, 0.4mA). The conditioned stimulus-uncon-
ditioned stimulus pairings were separated by 1-min intervals.
After completion of training, the mice remained in the condi-
tioning chamber for 1 min and were returned to their home
cages. For the immediate foot shock control, mice were put in
the fear conditioning chamber, and a foot shock was immedi-
ately delivered (2 s, 0.4 mA); 30 s latter, they were returned to
their home cages. Mice remained in their home cages for 30
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min before being anesthetized with 3% isoflurane (2 liters/min
O2) and transcardially perfused with 4% PFA. Following fixa-
tion, brains were immediately removed and further fixed over-
night in 4% PFA.
Immunohistochemistry of Mouse Brain—Brains were pro-
cessed in paraffin wax and sliced at 5 m using a microtome.
Following antigen retrieval, sections were washed in TBS con-
taining 0.1% Triton X-100 and blocked for 2 h at room temper-
ature in TBS, 0.1% Triton X-100, 10% goat serum, and 5% BSA.
Sections were incubated with antibodies to c-Fos (Santa Cruz
Biotechnology), ARC (Santa Cruz Biotechnology), and M1
AChR phospho-specific serine 228 at 2.5 g/ml in blocking
buffer (overnight at 4 °C). Sections were washed three times,
and incubated with Alexa FluorTM 488 fluorescent secondary
antibodies for 1 h at room temperature in blocking buffer. Fol-
lowing three washes, slices weremounted in Vectashield Hard-
SetTM mounting medium with DAPI. All images were taken
using a Zeiss confocal microscope with Zen software (Zeiss).
Assay for ERK Activity—Extracellular signal-regulated pro-
tein kinase 1/2 phosphorylation assay in CHO-M1 cells were
seeded into transparent 96-well plates at 35,000 cells/well and
grown overnight at 37 °C. Cells were washed with PBS and
incubated in serum-free -minimal essential medium at 37 °C
for at least 4 h. Cells were incubated with varying concentra-
tions of agonist in the presence and absence of increasing con-
centrations of an allosteric compound for 5 min (compounds
were co-added). The reaction was terminated by the removal of
compounds and addition of 50 l of SureFire lysis buffer. The
lysates were agitated for 30 min at room temperature, and 4 l
of each lysate was transferred into a 384-well opaqueOptiplate.
SureFire detection mix (7 l/well) consisting of detection re-
agent, activation reagent, donor beads, and acceptor beads
(660:110:11:11 v/v) were added to the plate. Plates were incu-
bated in the dark at room temperature for 2 h with gentle agi-
tation before the fluorescence signal was measured using a
PheraStarTM plate reader.
Generation of M1 DREADD Mice—Transgenic C57BL6/J
mice, which express a humanized, mutated form of the M1
mAChR, were generated by genOway (Lyon, France). Briefly,
humanizingmutations V5A, S254T, K320R, G337A, and V413I
were introduced into the mouse coding sequence to make the
corresponding amino acid sequence identical to the humanM1
mAChR. In addition, two point mutations, Y106A and A195G,
were introduced that render theM1mAChR insensitive to ace-
tylcholine and promote sensitivity to the synthetic compound
clozapine-N-oxide (CNO). This receptor mutant was termed
the M1 DREADD receptor. Finally, an HA tag sequence YPY-
DVPDYA was appended to the C terminus followed by a stop
codon. The gene-targeting construct consisted of long and
short homology arms. The long arm consisted of a 5268-bp
fragment containing the 3 part of intron 2; this was generated
by PCR from genomic DNA template using primers 85426GAlm
5 GGGGACAACTTTGTATAGAAAAGTTGTTGGGAGG-
ATGCAGCCTCTCCA and 85427GAlm 5 GGGGACTGC-
TTTTTTGTACAAACTTGGGCGCGCCACGTACGCCT-
CTTCAAGGCTTAAGTGGAATGAAGGGGCAGCCCC. The
short arm consisted of a 3188-bp fragment containing the
3UTR sequence of exon 3 that was amplified from genomic
DNA using primers 85424GAsm 5 ACTGTCAACCCCAT-
GTGCTACGCAC and 85425GAsm 5GGGCTACAAGGGA-
GCATGAACAAGC. A diphtheria toxin negative selection cas-
sette was included to allow for selection of ES cells that had
undergone homologous recombination, and a positive selec-
tion neomycin gene and a STOP of transcription cassette
flanked by loxP sites were inserted upstream of the CHRM1
coding sequence. This construct was transfected into C57BL6
ES cells that were selected using neomycin. Resistant colonies
were screened to verify correct integration of the 5 and 3 ho-
mology arms by PCR using primers 85488 5 GCAGGTCGA-
GGGACCTAATAACTTCG and 85489sa 5AAGCTCTCAA-
GGTCCAACAGTTTCTGG for short arm integration and
primers 85487la 5 AGTCTTACCAGGGAAGAAAGCCTG-
ATCC and 0070-Neo-16219sa 5CCTGCTCTTTACTGAAG-
GCTCTTTACTATTGC for long arm integration.
Positive clones were expanded and injected into blastocysts
derived from C57BL6/J female mice to generate chimeric ani-
mals that were then bred with C57BL6 wild-type C57BL6 mice
to generate heterozygous F1 animals. The neomycin/STOP
cassette was excised by breeding heterozygous animals with
Cre deleter mice to generate M1 DREADD constitutive
knock-inmice. Genotyping was performed by PCR on genomic
DNA obtained from tail biopsies using primers mM1 451 for-
ward 5 TTG GTT TCC TTC GTT CTC TGG GC and mM1
1227 reverse 5GACGTAGCAAAGCCAGTAGCCCAGC.
The resulting PCRproductswere subjected to restriction diges-
tion with SacI, the products of which discriminated between
WTC57BL6 and heterozygous and homozygousM1DREADD
animals.
Results
Determination of the Phosphorylation Sites on the M1
mAChR—Our initial evaluation of the phosphorylation sta-
tus of the M1 mAChR was conducted on Chinese hamster
ovary cells expressing the mouse M1 mAChR (CHO-M1
cells) stimulated with the natural ligand acetylcholine or the
M1/M4-preferring agonist xanomeline (Fig. 1A) (19, 20).
These two ligands stimulated inositol phosphate production
in a concentration-dependent manner with acetylcholine
and xanomeline both acting as full agonists (Fig. 1A).
In phosphorylation studies, where total receptor phos-
phorylation was determined using metabolically labeled
CHO-M1 cells, bothmuscarinic agonists increased the phos-
phorylation status of M1 mAChRs (Fig. 1B). To establish the
precise sites of phosphorylation, a mass spectrometry-based
phosphoproteomic study was conducted that identified nine
serine and three threonine phosphorylation sites in the third
intracellular loop of the receptor, as well as two serine phos-
phorylation sites in the C-terminal tail (Fig. 1, C–F). Four of
these sites at serine residues 228, 273, 322, and 451 (Ser228,
Ser273, Ser322, and Ser451) were selected for the generation of
phospho-specific antibodies based on the antigenicity of the
sites.
The phospho-specific nature of the antibodies generatedwas
tested by immunoprecipitation ofM1mAChRs fromCHO-M1
cells (using antibodies that recognized the HA epitope engi-
neered at the C terminus of the receptor) followed by treatment
Biosensor That Detects ActivatedM1mAChR
APRIL 22, 2016•VOLUME 291•NUMBER 17 JOURNAL OF BIOLOGICAL CHEMISTRY 8865
 at G
lasgow
 U
niversity Library on February 2, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of the immunoprecipitate with calf intestinal alkaline phospha-
tase (CIAP) to remove the phosphate groups (Fig. 2A). Control
immunoprecipitates were treated with vehicle. The immuno-
precipitates were then probed in Western blots with the phos-
pho-specific antibodies. In these experiments, treatment with
CIAP removed the immunoreactivity for the M1 mAChR of all
four phospho-specific antibodies (Fig. 2B) confirming that the
antibodies were all phospho-specific.
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Agonist-dependent M1 mAChR Phosphorylation—We next
used the phospho-specific antibodies to determine whether
phosphorylation on Ser228, Ser273, Ser322, and Ser451 was regu-
lated by agonist stimulation. Probing lysates derived from
CHO-M1 cells stimulated with vehicle, acetylcholine, or
xanomeline in Western blots using the phospho-specific anti-
bodies revealed that there were low levels of basal phosphory-
lation on residues Ser228 and Ser273 but that agonist treatment
significantly increased phosphorylation at these residues (Fig.
3). This is in contrast to phosphorylation at Ser451 that showed
notable basal phosphorylation that was only increased to a
small extent in response to agonist treatment (Fig. 3). This was
compared with phosphorylation at Ser322 that demonstrated
high levels of basal phosphorylation and showed no substan-
tive change in response to agonist (Fig. 3). In this respect, our
panel of phospho-specific antibodies revealed that different
phosphorylation sites on the M1 mAChR had different sen-
sitivities to agonist stimulation.
Because the antibody used to detect phosphorylation at
Ser228 gave a strong signal and phosphorylation at this site was
exquisitely agonist-sensitive, this antibody was considered an
excellent candidate for a biosensor that would identify the acti-
vated M1 mAChR receptor and as such was characterized
further.
Determination of Changes in M1 mAChR Phosphorylation in
Response to an Allosteric Ligand—The above data demon-
strated that the activated state of theM1mAChR in response to
two orthosteric agonists (acetylcholine and xanomeline) could
be established by monitoring the phosphorylation status of the
receptor at Ser228. It is now well understood that the active
FIGURE 1. Agonist-mediated phosphorylation of the M1 mAChR. A, CHO cells expressing a C-terminally tagged mouse M1 mAChR (CHO-M1 cells)
were treated with various concentrations of the muscarinic receptor agonists, acetylcholine (ACh) and xanomeline (Xan). Cells were then lysed and the
inositol phosphate levels determined. Shown is the mean data of three experiments  S.E. B, phosphorylation of the M1 mAChR was monitored in
CHO-M1 cells metabolically labeled with [32P]orthophosphate and treated with vehicle, acetylcholine (100 M), or xanomeline (Xan, 10 M) followed by
immunoprecipitation, gel electrophoresis, and autoradiography. Also shown are the mean data of five experiments S.E. The total M1 mAChR was also
established using an anti-HA in a Western blot (Loading Control). C, summary of the mass spectrometric determination of the phosphorylation sites on
the M1 mAChR. The phospho-sites indicated in redwere the sites to which phospho-specific antibodies were raised. D, representative MS/MS spectrum
and fragmentation table of M1 mAChR peptide phosphorylated on Ser
228. E, summary of all the M1 mAChR phosphopeptides obtained from five
experiments. Phosphorylated amino acids are highlighted in red. F, primary amino acid sequence of the human M1 mAChR receptor highlighting the
phosphoacceptor sites in red.
FIGURE 2. Characterization of M1 mAChR phosphorylation-specific antibodies. A, schematic representation of the experimental procedure used to
characterizeM1mAChRphosphorylation-specific antibodieswhereCIAPwas used todephosphorylate immunoprecipitatedM1mAChR receptor derived from
cells thathadbeen treatedwithacetylcholine (ACh) beforebeingprobed inWesternblotswith thephospho-specific antibodies.B, results ofWesternblots from
the experiments that are illustrated in A. Blots were probedwith phospho-specific antibodies directed toward Ser(P)228, Ser(P)273, Ser(P)322, and Ser(P)451. Also
shown is the loading control from this particular experiment using an anti-HA antibody to detect the epitope-tagged M1 mAChR. The * indicates slight
cross-reactivity of the phospho-specific antibodies with CIAP.
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conformation of GPCRs can also be promoted by ligands that
bind at allosteric sites (Fig. 4A) (21, 22). Previous studies had
established that the compound, 1-(4-methoxybenzyl)-4-oxo-
1,4-dihydroquinoline-3-carboxylic acid (benzyl quinolone car-
boxylic acid; BQCA), is a selective positive allosteric modulator
(PAM) to theM1mAChR (23–25).We confirm these studies by
establishing in our system that BQCA can promote acetylcho-
line binding at the M1 mAChR with a cooperativity factor of
100 ( factor  128; Fig. 4B). The enhanced binding of ace-
tylcholine observed in the presence of BQCA was correlated
with an augmentation of acetylcholine signaling as demon-
strated by a leftward shift in the InsPx concentration-response
curve to acetylcholine when conducted in the presence of
BQCA (cooperativity  factor  85; Fig. 4C). Hence, BQCA
was seen to promote the active conformation of the M1
mAChR,whichwas reflected in the ability of BQCA to augment
agonist binding and agonist-mediated signaling.
Based on these observations, and given that phosphorylation
at Ser228 likely reflects the proportion of M1 mAChRs in an
agonist-occupied (R*) conformation, we reasoned that BQCA
would promote acetylcholine-mediated phosphorylation at
Ser228. This was indeed the case, with BQCA mediating an
100-fold shift in the potency of acetylcholine-mediated phos-
phorylation at Ser228 (pEC50 (	logM) for acetylcholine 7.5
0.1 and pEC50 for acetylcholine in the presence of BQCA (3
M)  8.9  0.3; Fig. 4E). Thus, phosphorylation at Ser228 not
only reflected the action of orthosteric ligands at the M1
mAChR (Fig. 3), but also reported the action of an allosteric
modulator at this receptor.
These phosphorylation experiments were conducted with
BQCA at a concentration that in itself gave no response (i.e. 3
M), but rather it acted to enhance acetylcholine responses (i.e.
a concentration where BQCA acted as a PAM). However, at
higher concentrations, BQCA could be seen to act as an agonist
in its own right (23, 25). The agonist properties of BQCA can be
readily determined in pERK1/2 assays that, due to the high cou-
pling efficiency between the M1 mAChR and pERK1/2 signal-
ing in this system, were sufficiently sensitive to detect the ago-
nist action of BQCA (Fig. 4D). Thus, high concentrations of
BQCA in a pERK1/2 assay showed a direct agonist action (Fig.
4D). This agonist activity was reflected in complex concentra-
tion-response curves, where increasing concentrations of
BQCA in the presence of very low concentrations of acetylcho-
line revealed the agonist activity of BQCA (green arrow, Fig.
4D), whereas higher concentrations of acetylcholine revealed
mixed agonist and PAM activities of BQCA (black arrow, Fig.
4D). Importantly, when examined in phosphorylation studies, it
was seen that at a high concentration (100M) BQCAmediated
phosphorylation at Ser228 to a similar extent as that seen with a
maximal concentration of acetylcholine (500 M) (Fig. 4F). In
contrast, a low concentration of BQCA (3 M) alone did not
stimulate any change in receptor phosphorylation (Fig. 4F).
Phosphorylation at Ser228 was further characterized in
immunocytochemistry studies. In these studies, the Ser228
phospho-specific antibody detected very little immunoreactiv-
ity in non-transfected CHO cells and in CHO-M1 cells under
basal conditions (Fig. 4G). However, following agonist treat-
ment (acetylcholine, 5 min) or treatment with a high concen-
tration of BQCA (100 M), punctate cytoplasmic staining was
detected (Fig. 4G). Interestingly, the punctate localization of
the phosphorylated M1 mAChR represented only a small pro-
portion of the total receptor population (identified using the
antibodies against the HA epitope tag) that, after a 5-min stim-
ulation, appeared concentrated at or very close to the plasma
membrane (Fig. 4G).
By combining all these data, it can be concluded that musca-
rinic ligands that promote the transition of the receptor froman
inactive R-state to an active R*-state promote phosphorylation
of the M1 mAChR on Ser228. This includes orthosteric ligands,
such as acetylcholine and xanomeline, as well as allosteric
ligands (i.e. BQCA). In this sense, Ser228 phosphorylation is an
ideal sensor of receptor activation, because this phosphoryla-
tion event reflects activation of the receptor regardless of the
mechanism of activation.
Determination of the Active Conformation of the M1 mAChR
during Memory Acquisition and Drug Treatment—The data
presented above support the notion that phosphorylation of
Ser228 on the M1 mAChR can act as a biosensor for receptor
activation in response to either orthosteric or allosteric ligands.
To test whether this could be used to monitor the activation
status of the M1 mAChR in vivo, we first employed a novel
mouse model where the wild-type M1 mAChR gene was
humanized so that the translated amino acid sequence was
identical to the human M1 mAChR and where an HA epitope
tag was inserted at the C terminus. Two further point muta-
tions were introduced into the orthosteric binding site (Y106A
and A195G) (Fig. 5A), which resulted in an HA-tagged human-
ized M1 mAChR mutant that was unable to be activated by the
natural ligand acetylcholine but rather could be activated by the
synthetic drug CNO (26, 27). This receptor mutant has been
FIGURE 3.Agonist-dependent phosphorylation revealedbyphospho-specific antibodies to theM1mAChR.M1mAChRswere immunoprecipitated from
non-transfected (NT) CHO cells or CHO-M1 cells that were treated with vehicle, acetylcholine (ACh, 100M), or xanomeline (Xan, 10M) for 5 min, resolved by
SDS-PAGE, and probed in Western blots with phospho-specific antibodies raised against Ser(P)228, Ser(P)273, Ser(P)322, and Ser(P)451. Total M1 mAChR was
determined in the loading control using anti-HA antibodies. The experiment shown is typical of at least five independent experiments.
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previously described and characterized in vitro and termed as a
M1 DREADD (26). The design of this mouse means that
expression of theM1 DREADDwill be under the control of the
native M1 mAChR promoter ensuring that the M1 DREADD
would be expressed in the same cell types and at the same
expression levels as the native M1 mAChR.
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Analysis of the ability of acetylcholine and CNO to induce
phosphorylation of the M1 DREADD was tested in transfected
cells. It was found that acetylcholine had no significant effect on
M1 DREADD phosphorylation at Ser228 (Fig. 5B). In contrast,
the M1 DREADD was phosphorylated by CNO in a concen-
tration-dependent manner (Fig. 5B). Immunohistochemical
labeling of the HA epitope tag identified expression of the M1
DREADD mutant in the molecular layer of the CA1 region of
the hippocampus (Fig. 5C). Using the Ser228 phospho-specific
antibody in M1 DREADD identified light immunohistochemi-
cal staining in the CA1 region of the hippocampus that was
up-regulatedwithin 30min of intraperitoneal administration of
CNO (Fig. 5D).
Co-staining with anti-HA, to reveal the expression of the
M1-DREADD HA-tagged receptor, and the Ser228 phospho-
specific antibody revealed neurons where the M1-DREADD
receptor existed in a phosphorylated state (indicated by arrows
in Fig. 5E). Interestingly, not all of the M1-DREADD-express-
ing neurons stained with the phospho-specific Ser228 antibody
suggesting that in some neurons the M1 receptor remained
non-phosphorylated (at least at this residue) (Fig. 5E). It should
be noted that M1-KO controls also revealed some weak non-
specific nuclear staining with the Ser228 phospho-specific anti-
body (Fig. 5, D and E).
The data in theM1DREADDmice supported the notion that
the Ser228 phospho-specific antibody can be used to monitor
M1 mAChR activation following stimulation by a synthetic
ligand.We therefore tested this further by the administration of
xanomeline (5 mg/kg i.p.) into wild-type mice followed by
immunohistochemical analysis of phosphorylation at Ser228.
Pharmacokinetic analysis determined that xanomeline levels in
the brain peaked 30 min after injection. At this time the animal
was sacrificed by perfusion fixation, and the brain was removed
and sectioned for immunohistochemical staining. This proce-
dure revealed phosphorylation of the M1 mAChR at Ser228 in
the neuronal cell bodies in the pyramidal layer of the CA1
region of the hippocampus (Fig. 6A). In contrast, low levels of
staining were observed in vehicle-treated mice (Fig. 6A).
To test whether phosphorylation at Ser228 could also act as a
biosensor for M1 mAChR activation in response to the admin-
istration of a PAM,BQCAwas administered at 15mg/kg, which
resulted in a free concentration of BQCA in the hippocampus
of 51.8  3.6 nM; a concentration where BQCA would show
PAMactivity at theM1mAChR. In these experiments,Western
blots of hippocampal lysates prepared fromBQCA-treated ani-
mals showed an increase in the phosphorylation status of the
M1 mAChR at Ser228 in response to BQCA (Fig. 6, B and C).
M1 mAChR Is Activated during Memory Acquisition—Hav-
ing demonstrated that the action of an orthosteric agonist and a
PAM at the M1 mAChR in the hippocampus could be moni-
tored using the phosphorylation status of the M1 mAChR at
Ser228, we next asked whether the phosphorylation of Ser228
could also be used as a biosensor for M1 mAChR activation
during a physiological process. Previous studies had implicated
a role for the M1 mAChR in learning and memory (15–17).
Because the M1 mAChR is highly expressed in the hippocam-
pus (28), an area associated with learning and memory, we
asked whether changes in the phosphorylation status of Ser228
on M1 mAChRs could be detected in the hippocampus follow-
ing fear conditioning training, a classical protocol used to
induce a learning response (29). The mice were therefore sub-
jected to fear conditioning training and 30 min were later sac-
rificed, tissues fixed by transcardial perfusion, and brains sec-
tioned and probed with phospho-specific antibodies to Ser228
phosphorylation. In these experiments, an increase in the phos-
phorylation status of Ser228 was observed in the stratum pyra-
midale of the CA1 region of the hippocampus following fear
conditioning training when compared with an immediate
unpaired foot shock control (Fig. 6D). Importantly, this
increase in Ser228 phosphorylation correlated with an increase
in c-Fos immunoreactivity, a marker of neuronal activity (Fig.
6D).
Discussion
Here, we show that phosphorylation at serine 228 in the third
intracellular loop of the M1 mAChR can be used as a read-out
for receptor activation. Using this antibody as a biosensor for
the activated receptor, we show that the M1 mAChR is acti-
vated in the hippocampus following fear conditioning training.
This correlates with an increase in neuronal activity in the hip-
pocampus thereby strongly supporting a link between hip-
pocampal M1 mAChR activity and hippocampus-based learn-
ing and memory (15–17). Our study also illustrates how
analysis of GPCR phosphorylation status can be used to assess
the activation of receptors following drug treatment. Establish-
ing target-drug engagement is highly valued in drug discovery,
but up to now, no method has been described to monitor this
for a GPCR target.
FIGURE4.Positiveallostericmodulator (BQCA)promotesM1mAChRphosphorylationat Ser
228.A, schematic representationof theM1mAChR illustrating
distinct bindingmodes for orthosteric ligands, acetylcholine (ACh) and xanomeline (Xan), from that of allosteric ligands, such as BQCA. The chemical structure
of BQCA is also shown. B, CHO-M1 cell membranes were used in competition radioligand binding experiments where acetylcholine displacement of [3H]NMS
was tested in the presence of a range of concentrations of BQCA. The data presented are means  S.E. of three independent experiments conducted in
triplicate. C, PAM activity of BQCAwas revealed in concentration-response curves for acetylcholine-mediated inositol phosphate production in CHO-M1 cells
in the presence of various concentrations of BQCA. D, both the mixed agonist (green arrow) and PAM (black arrow) activity of BQCA was revealed in concen-
tration-response curves for acetylcholinepERK1/2 response inCHO-M1cells in thepresenceof various concentrationsof BQCA. E, representativeWesternblots
of CHO-M1 cell lysates stimulated with increasing concentrations of acetylcholine in the presence or absence of BQCA (3 M) and probed with the phospho-
specific serine 228 antibody or anti-HA antibodies as a loading control for totalM1mAChR. Also shownare themeandata of three independent experiments
S.E.NT, non-transfected cells. F, CHO-M1 cells were stimulated with a high concentration of acetylcholine ( 500M) or with BQCA at two concentrations; a low
concentration (3M)where BQCAmight be expected to showno intrinsic agonist activity and a high concentration (100M)where BQCAwould showagonist
activity. Cell lysates were prepared, resolved by SDS-PAGE, andWestern blots probed with the phospho-specific serine 228 antibody. The IgG band was used
as a loading control in these experiments. Also shown is the mean data  S.E. of Western blots from three independent experiments. G, CHO-M1 cells
stimulated with acetylcholine or BQCA were fixed and processed for immunocytochemistry using an anti-HA antibody to show total M1 mAChR or with the
phospho-specific serine 228. Non-transfected CHO cells were similarly treated. All the images and gels shown were typical of at least three independent
experiments. All the graphical data represent the mean S.E. of at least three independent experiments. Statistical analysis uses Student’s paired t test.
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To establish the phospho-specific antibody to Ser228 as a sen-
sor for M1 mAChR activation, we first conducted a mass spec-
trometry-based phosphoproteomic analysis of the M1 mAChR
expressed in a recombinant system. This revealed that the M1
mAChR, likemany otherGPCRs (30, 31), ismultiply phosphor-
ylated at sites within the third intracellular loop andC-terminal
FIGURE 5. Phosphorylation of Ser228 on the M1 DREADD receptor could be detected in the hippocampus following receptor activation with a
selective agonist. A, illustration of the two point mutations (Y106C and A195G) used to generation the HA epitope-tagged M1 DREADD receptor
mutant in which activation by acetylcholine (ACh) is abolished but instead the receptor could be activated by CNO. B, CHO FlpIn cells expressing the
HA-tagged M1 DREADD receptor were stimulated with increasing concentrations of acetylcholine or CNO. Western blots (WB) were probed with either
anti-HA (as a loading control) or phospho-specific serine 228 antibodies. NT, non-transfected cells. C and D, M1 DREADD knock-in mice or M1 mAChR-
knock-out mice (M1-KO) were injected (intraperitoneally) with CNO (0.3 mg/kg). After 30 min tissue was fixed by transcardial perfusion and sections
stained with anti-HA antibodies (C) or phospho-specific serine 228 antibodies (D). E, fixed sections from M1 mAChR knock-out mice (M1-KO) or M1
DREADD knock-in mice treated with vehicle or CNO (0.3 mg/kg) were co-stained with anti-HA (green) and anti-phospho-specific serine 228 (red)
antibodies. Two neuronswhere the staining for the receptor and the phosphorylated receptor occur in the same neuron are indicated by the arrows. The
areas marked by the white box are magnified in the lower panels.
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tail. The multisite nature of M1 mAChR phosphorylation is
consistent with the suggestion made by us, and others, that the
complex pattern of receptor phosphorylation is cell type-spe-
cific. This idea led to the notion that a receptor expressed in
different cell typesmight show a different phosphorylation pat-
tern, and this pattern would contribute to cell type-specific
receptor signaling and regulation (30, 32, 33). This notion has
been coined the receptor phosphorylation bar code (30, 32) and
has been further extended to suggest that different agonists
might drive different patterns of phosphorylation in a manner
that encodes for different signaling outcomes (30, 32, 33). In
this way, the phosphorylation bar code is thought to contribute
to stimulus bias where a ligand can direct signaling down one
pathway in preference to another (34, 35), possibly by mediat-
ing a specific pattern of receptor phosphorylation.
Given the notion that phosphorylation of GPCRs might be a
dynamic process regulated, at least in part, by the pharmaco-
logical properties of the agonist used to stimulate the receptor,
FIGURE 6. M1 mAChR is activated in the hippocampus following drug treatment and memory acquisition. A, C57/BL6/NTAC mice were injected
(i.p.) with vehicle or xanomeline (5 mg/kg). After 30 min, tissues were fixed by transcardial perfusion, and sections were obtained and stained with the
phospho-specific serine 228 antibody and with DAPI stain to reveal the nuclei. Shown are representative sections through the CA1 region of the
hippocampus. B, C57/BL6/NTAC mice (Wild-Type) or M1 mAChR-knock-out mice (M1-KO) were injected (intraperitoneally) with BQCA (15 mg/kg) or
vehicle, and after 30min hippocampal membranes were prepared fromwhich theM1mAChRwas immunoprecipitated. The sample was then processed
in Western blots, which were probed with phospho-specific serine 228 antibody or an M1 mAChR-specific antibody to detect total M1 mAChR. C,
quantification of Western blots from B. The data are presented as means S.E. (n 3). Statistical analysis uses Student’s paired t test. D, C57/BL6/NTAC
mice were subjected to a fear conditioning training protocol or to an unpaired immediate foot shock as a control; 30 min later tissue was fixed by
transcardial perfusion, and sections obtained and stained with phosphorylated Ser228-specific antibody (upper panel) or anti-c-FOS antibody (lower
panel). All the data shown are typical of at least three independent experiments.
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it was important in this study to carefully characterize the ago-
nist dependence of the phosphorylation events revealed by the
mass spectrometry studies. Hence, we generated a panel of
phospho-specific antibodies to the M1 mAChRs that could be
used to further probe at least 4 of the 14 sites of phosphoryla-
tion. First, all four of the antibodies generated were phospho-
specific recognizing phosphorylation at Ser228, Ser273, Ser322,
and Ser451. These antibodies established that there were high
levels of constitutive phosphorylation at Ser322 and Ser451. In
contrast, phosphorylation at Ser228 and Ser273 was seen to be
highly sensitive to agonist stimulation and showed little phos-
phorylation in the basal state. Thus, phosphorylation at Ser228
and Ser273 appeared to fit the traditionally held view that only
the agonist-occupied receptor undergoes phosphorylation (36,
37), and thus these sites were ideal candidates as sensors of the
activated receptor.
Because of the high signal-to-noise ratio obtained with the
phospho-specific antibody to phosphorylated Ser228, we used
this in further studies and established that orthosteric agonists,
acetylcholine and xanomeline, mediated phosphorylation of
Ser228. Furthermore, the positive allosteric modulator, BQCA,
was also able to drive Ser228 phosphorylation. Hence, it would
appear that at least in the case of Ser228 phosphorylation, all
ligands that promoted the transition of the receptor from an
inactive R-conformation to an active R*-conformation resulted
in phosphorylation of the receptor on Ser228 despite having
different pharmacological properties. In this sense, an antibody
that specifically recognized Ser228 phosphorylation could be
considered as a biosensor of the active R*-conformation of M1
mAChR.
It is important to point out that not all phosphorylation sites
on GPCRs will show the characteristics of Ser228 phosphoryla-
tion described here. Careful evaluation of the agonist sensitivity
of the phosphorylation event with a range of pharmacological
ligandswould need to be conducted because other sites of phos-
phorylationmight be less sensitive to agonist stimulation (such
as Ser322 andSer451) ormight showdifferent levels of phosphor-
ylation in response to ligands. Such phosphorylation sites
would not be suitable as indicators of receptor activation.
To determine whether the phospho-specific Ser228 anti-
body could be used to detect phosphorylation (and thereby
activation) of the M1 mAChR in vivo, we employed a mutant
mouse line that expressed a M1 DREADD receptor in place
of the wild-type M1 mAChR. This receptor could be selec-
tively activated by CNO in vivo (26). Importantly, our in vitro
studies had established that CNO stimulated phosphoryla-
tion at Ser228 on the M1 DREADD. We show here that the
M1 DREADD expressed in the CA1 region of the hippocam-
pus was phosphorylated on Ser228 following administration
of CNO. These data confirmed the hypothesis that the phos-
pho-specific Ser228 antibody could be used to identify acti-
vated receptors in the hippocampus. This was further sup-
ported by receptor stimulation using xanomeline and BQCA
in wild-type animals, where receptor activation could simi-
larly be identified by an up-regulation of phosphorylation at
Ser228.
Given that phosphorylation at Ser228 fit the criteria for use as
a biosensor for receptor activation, we investigatedwhether the
M1 mAChR was activated in the hippocampus during memory
acquisition. Previous studies had established a role for musca-
rinic receptor signaling in learning and memory (14, 38, 39).
The involvement of theM1mAChR in this process is suspected
not only because this receptor subtype is highly expressed in the
hippocampus (28) but also because gene knock-out and phar-
macological disruption of M1 mAChRs resulted in defective
learning andmemory (14). Thus, there is a great deal of interest
in targeting the M1 mAChR as a mechanism to treat cognitive
deficits in neurodegenerative disease, such as Alzheimer dis-
ease (14, 40, 41). Despite this, it is still unclear whether M1
mAChRs acting directly at the level of the hippocampus medi-
ate memory processing or whether these receptors are more
subtly involved by promoting interactions between the pre-
frontal cortex and hippocampus (16, 42–44). We were there-
fore interested to test the possibility that M1 mAChRs were
activated in the hippocampus duringmemory acquisition. This
was found to be the case with a significant up-regulation of M1
mAChR phosphorylation at Ser228 following fear conditioning
training in the CA1 region of the hippocampus. Importantly,
this region was also seen to show high levels of neuronal activ-
ity, as indicated by an increase in c-FOS expression, following
fear conditioning training. These data support the hypothesis
that hippocampal M1 mAChRs are activated during memory
acquisition and that thismay contribute to the process of learn-
ing and memory.
In conclusion, by determining the phosphorylation sites
within the M1 mAChR and generating and characterizing the
phospho-specific antibodies, we have established that at least
one of the phosphorylation events (Ser228) is exquisitely sensi-
tive to agonist stimulation. Using this phosphorylation event as
a biosensor for receptor activation, we have been able to estab-
lish the activation of the M1 mAChR in vivo in the CA1 region
of the hippocampus following drug treatment and memory
acquisition.
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